Sign up to save your podcasts
Or
Share Optimizing Outcomes for Patients with Relapsed or Refractory CLL/SLL
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Optimizing Outcomes for Patients with Relapsed or Refractory CLL/SLL
CME credits: 0.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-for-patients-with-relapsed-or-refractory-cllsll/13797/
The landscape of treatment for CLL is rapidly evolving, with promising results from trials examining chemotherapy-free regimens in the frontline setting. While these targeted approaches utilizing BTK or BCL-2 inhibitors have largely displaced chemoimmunotherapy in frontline management of CLL, there remains a clinically significant fraction of patients who will require subsequent therapy after developing drug intolerance or progressive disease. Join Drs. Andrew Lipsky and Jacob Soumerai as they strategize which targeted therapeutic options for relapsed/refractory CLL likely offer each individual patient the safest and most effective clinical outcome.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-for-patients-with-relapsed-or-refractory-cllsll/13797/
The landscape of treatment for CLL is rapidly evolving, with promising results from trials examining chemotherapy-free regimens in the frontline setting. While these targeted approaches utilizing BTK or BCL-2 inhibitors have largely displaced chemoimmunotherapy in frontline management of CLL, there remains a clinically significant fraction of patients who will require subsequent therapy after developing drug intolerance or progressive disease. Join Drs. Andrew Lipsky and Jacob Soumerai as they strategize which targeted therapeutic options for relapsed/refractory CLL likely offer each individual patient the safest and most effective clinical outcome.
=